Miller, a leader in empirical bioethics and developing and using metrics to enhance pharmaceutical industry accountability, would love to get our faculty in the Section of General Internal Medicine and at the Yale School of Medicine more involved. “This is a magazine that I think could could help elevate the visibility on Yale’s projects with an equity, ethics or social responsibility focus,” shared Miller. Cary Gross, MD, and Joseph Ross, MD, MHS, also in the Section of General Internal Medicine, have taken up that call by authoring articles for the launch, in addition to serving as advisers on the magazine masthead.
The idea for the new magazine was first hatched in 2016 when Abbate and Miller met at the Biotechnology Industry Organization (BIO) International Convention, held that year in California. At that meeting, Miller presented the results of the inaugural Good Pharma Scorecard pilot—a ranking of new FDA approved drugs and their pharmaceutical company manufacturers on their clinical trial transparency. After years of phone calls, emails and meetings, everything came together, and they were given the green light to move ahead!
Through careful reporting and expert-written commentary, Good Medicine explores the intersection of science and moral responsibility. Drug pricing, patient privacy in the age of digital medicine, conflicts of interest, equity in care, and other critical concerns and challenges faced by the biopharma industry are explored and the ways in which collectively we can ensure that medicine serves the interests of patients everywhere. The January pilot issue is here. The next print publication is targeted for June 2021 and will be available here.
This is a magazine that I think could could help elevate the visibility on Yale’s projects with an equity, ethics or social responsibility focus.
Jennifer Miller, PhD